Dyne Therapeutics, Inc.
NMS: DYNLive Quote
About Dyne Therapeutics, Inc.
Healthcare
Biotechnology
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Dyne Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -55.7%, which indicates that capital utilization is currently under pressure.
At a current price of $18.68, DYN currently sits at the 65th percentile of its 52-week range (Range: $7.01 - $25.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$2.78B
Trailing P/E
--
Forward P/E
-6.16
Beta (5Y)
1.28
52W High
$25.00
52W Low
$7.01
Avg Volume
2.16M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App